- Home
- NVCT vs PDT Comparison
NVCT vs PDT Comparison
Compare NVCT & PDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVCT | PDT |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 721.2M | 653.2M |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | NVCT | PDT |
|---|---|---|
| Price | $19.08 | $12.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 589.5K | 123.5K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $12.53 |
| 52 Week High | $29.28 | $13.65 |
Technical Indicators
Market Signals| Indicator | NVCT | PDT |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 47.52 |
| Support Level | $18.02 | $12.87 |
| Resistance Level | $29.28 | $12.97 |
| Average True Range (ATR) | 1.26 | 0.09 |
| MACD | -0.50 | -0.01 |
| Stochastic Oscillator | 38.24 | 19.94 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.